$LIVN

Bianchi Francesco sold $136K of LIVN

Bianchi Francesco sold 1,800 shares of LivaNova PLC (LIVN) at $75.75 ($0.14M total) on 2026-05-26.

Original reporting
SEC EDGAR · Bianchi Francesco
Published May 27, 2026, 8:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LIVN
Neutral
medium confidence
Mentioned
$LIVN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LIVNNeutralLow
01

Why it matters

Insider selling can modestly pressure sentiment, but without a fundamental catalyst it usually has limited impact on valuation.

02

Market read

Traders may monitor for follow-on selling or clustering of insider activity, but this single transaction is unlikely to drive a major repricing.

03

What to watch

No 10b5-1 plan is noted, but the article provides no context on taxes, diversification needs, or prior sale cadence; holdings remain sizable (7,228 shares after sale).

Relevance 6/10Timing: Immediate (new Form 4 filed 2026-05-27) but typically limited follow-through.

Background

The article is a SEC Form 4 insider transaction disclosure for LivaNova PLC (director selling shares).

Company-level read

Ticker impact

$LIVNNeutralMedium confidence
Context

Director Bianchi Francesco sold 1,800 shares of LivaNova on 2026-05-26 for ~$136.35K via an open-market sale (no 10b5-1 plan).

Expected impact

Low likelihood of a sustained move; any reaction is likely limited to short-term sentiment/positioning.

Evidence & confidence

The filing is a routine Form 4 transaction with no stated reason, and it does not include earnings, guidance, deals, or regulatory/drug catalysts.

Market effects

Minimal; insider selling in one medtech/neuromodulation name generally does not reset sector expectations.

None indicated; filing is US SEC EDGAR with no geographic catalyst.

None indicated; transaction is company-specific and not tied to global events.

Counterpoint

Insider sales can be routine liquidity/portfolio rebalancing and may not signal reduced confidence, especially absent any accompanying negative company news.

Key entities

  • LivaNova PLC

    Company whose director sold 1,800 shares via open-market sale; Form 4 filed 2026-05-27.

  • Bianchi Francesco

    Director who executed the sale; holdings after transaction were 7,228 shares.

Related articles

$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.

$LIVNHighAI 9/10

LivaNova Q2 Earnings Call Highlights

LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.

$LIVNHighAI 9/10

LivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.

$LIVNHighAI 9/10

Why is LivaNova stock climbing today?

LivaNova shares rose 1.3% in after-hours to $86.42 after the company reported Q2 2026 results. Adjusted EPS was $1.26 vs $1.09 expected, and revenue was $390.6M vs $380.57M. LivaNova raised full-year 2026 adjusted diluted EPS guidance to $4.30-$4.40 (midpoint $4.35). KeyBanc lifted its price target to $92 from $83.

$LIVNHigh

LivaNova PLC (LIVN): Results of Operations and Financial Condition

LivaNova PLC (LIVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q2026earningspressrelease.htm EX-99.1 Document EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered double-digit reported revenue growth of 10.8%, with constant-currency rev